Display options
Filter resources
Text Availability
Article type
Publication date
Showing 1 to 12 of 22 entries
Sorted by: Best Match Show Resources per page
Breathing frequency monitors.

Journal of clinical monitoring

Gluck MS, Haffner ME.
PMID: 3746372
J Clin Monit. 1986 Jul;2(3):209-10. doi: 10.1007/BF01620555.

No abstract available.

The relative efficacy of vestibular-proprioceptive stimulation and the upright position in enhancing visual pursuit in neonates.

Child development

Gregg CL, Haffner ME, Korner AF.
PMID: 1083792
Child Dev. 1976 Jun;47(2):309-14.

48 healthy neonates born to multiparae were randomly assigned to view a moving stimulus either in the horizontal or the upright position, with or without added vestibular stimulation and with or without pacifier sucking. The infant was shown a...

Two decades of orphan product development.

Nature reviews. Drug discovery

Haffner ME, Whitley J, Moses M.
PMID: 12360259
Nat Rev Drug Discov. 2002 Oct;1(10):821-5. doi: 10.1038/nrd919.

Over the past 20 years, incentives of the Orphan Drug Act (ODA), the largest single source of extramural clinical grants at the US Food and Drug Administration, have had a substantial impact on public health. ODA incentives have contributed...

Food and Drug Administration warning on dead space in tracheal tubes.


Haffner ME.
PMID: 6583655
Pediatrics. 1984 Mar;73(3):414.

No abstract available.

The need for worldwide policy and action plans for rare diseases.

Acta paediatrica (Oslo, Norway : 1992)

Forman J, Taruscio D, Llera VA, Barrera LA, Coté TR, Edfjäll C, Gavhed D, Haffner ME, Nishimura Y, Posada M, Tambuyzer E, Groft SC, Henter JI.
PMID: 22519914
Acta Paediatr. 2012 Aug;101(8):805-7. doi: 10.1111/j.1651-2227.2012.02705.x. Epub 2012 May 11.

UNLABELLED: There are more than 6000 rare diseases (defined as affecting

The Food and Drug Administration's Office of Orphan Products Development: incentives, grants, and special designations speed therapies for orphan diseases.

Retina (Philadelphia, Pa.)

Haffner ME.
PMID: 16374359
Retina. 2005 Dec;25(8):S89-S90. doi: 10.1097/00006982-200512001-00045.

No abstract available.

Malfunction of neonatal incubator.


Haffner ME.
PMID: 7069893
JAMA. 1982 May 07;247(17):2372.

No abstract available.

Health fraud: a growing problem.

Military medicine

Haffner ME, Farley D.
PMID: 3092138
Mil Med. 1986 Jul;151(7):374-9.

No abstract available.

Characteristics of crying and noncrying activity of full-term neonates.

Child development

Korner AF, Kraemer HC, Haffner ME, Thoman EB.
PMID: 4143885
Child Dev. 1974 Dec;45(4):953-8.

No abstract available.

Orphan products: origins, progress, and prospects.

Annual review of pharmacology and toxicology

Haffner ME.
PMID: 2064386
Annu Rev Pharmacol Toxicol. 1991;31:603-20. doi: 10.1146/annurev.pa.31.040191.003131.

No abstract available.

Evaluation of orphan products by the U.S. Food and Drug Administration.

International journal of technology assessment in health care

Haffner ME, Kelsey JV.
PMID: 1464485
Int J Technol Assess Health Care. 1992;8(4):647-57. doi: 10.1017/s0266462300002348.

Orphan drug products generally are used in treating or preventing rare diseases. The small number of patients available for study may create special problems in the evaluation of these products. This paper examines some of the special problems that...

Permanent perceptual and neurophysiological effects of visual deprivation in the cat.

Experimental brain research

Ganz L, Haffner ME.
PMID: 4844167
Exp Brain Res. 1974 Apr 30;20(1):67-87. doi: 10.1007/BF00239018.

No abstract available.

Showing 1 to 12 of 22 entries